Skip to content

Veracyte VCYT Price / book

Price / book at other companies

Guardant Health logo
Guardant HealthGH
36.8×
Natera, Inc. logo
Natera, Inc.NTRA
16×+0.6×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
1.1×+0.1×
Revvity logo
RevvityRVTY
1.4×-0.3×
Labcorp Holdings logo
Labcorp HoldingsLH
2.5×+0.2×
Quest Diagnostics logo
Quest DiagnosticsDGX
2.9×+0.2×

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.28B+10.7%
Enterprise value$4.05B+7.4%
P/E48.6×-68.3×
P/S7.9×-0.4×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Calculated from Veracyte’s reported figures.

Based on the most recent quarter.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's price / book?
Veracyte (VCYT) reported price / book of 1.9× in Q1 2026.
How has Veracyte's price / book changed year-over-year?
Veracyte's price / book decreased by 1.6% year-over-year, from 1.9× to 1.9×.
What is the long-term trend for Veracyte's price / book?
Over 5 years (2020 to 2025), Veracyte's price / book has grown at a -21.0% compound annual growth rate (CAGR), from 8.3× to 2.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.